Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN By Ogkologos - January 9, 2026 221 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the GORTEC 2018-01 NIVOPOST-OP study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Breast Cancer Patient Fights To Have Mastectomy During COVID-19 Restrictions And... May 12, 2020 Adding Sintilimab to Chemoradiotherapy Improves Event-Free Survival in Patients with High-Risk... June 24, 2024 Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR,... July 16, 2025 What to Know About Cancer Clinical Trial Matching Programs March 14, 2023 Load more HOT NEWS ESMO Virtual Congress 2020, 19-21 September [ESMO Media Alert] Analysis Shows Women with High Breast Cancer Recurrence Scores Benefit from... FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib... EMA Recommends Granting a Conditional Marketing Authorisation for Belzutifan
